OBJECTIVES: The objective of this study was to determine course and treatment of @entity955 ( @entity955 ) in nonagenarians. Incidence of @entity955 increases with age. Due to the demographic change in the industrialized world, an increase of @entity955 in the group of elderly and very elderly is expected in the next decades. However, only few data exist on the clinical relevance of @entity955 in @entity1 aged 89  years or older. DESIGN: Observational, mono-centric registry. SETTING: University hospital. @entity1 : Of the 11,888 @entity1 included in the Berlin @entity955 (BAF) Registry, 279 @entity1 aged 89  years or older were identified. All @entity1 presented to our hospital with @entity955 between January 2001 and December  2014. MEASUREMENTS: @entity955 type, symptoms, comorbidities, CHA2DS2-VASc and HAS-BLED, treatment strategy, and anticoagulant treatment were assessed at baseline. A composite of @entity385 ( @entity385 ), @entity1031 , @entity548 , and @entity204 was the primary endpoint. @entity64 / @entity385 , @entity1031 and @entity548 , presence of @entity955 , new onset of @entity712 and change of NYHA class, and @entity1168 necessitating pacemaker implantation were secondary endpoints. RESULTS: @entity1 (age 92      2.7  years, range 89-108) presented in EHRA class I in 38.4% of the cases, class II in 49.5%, class III in 10%, and class IV in 2%. Rhythm control was attempted in 37 (13.3%) of the @entity1 . Baseline CHA2DS2-VASc and HAS-BLED were 5.0      1.3 and 3.1      0.9, respectively. @entity1697 ( @entity1697 ) was initiated in 74 (26.5 %) of the @entity1 . Of all @entity1 , 33 (11.8%) @entity1 died in hospital. Of the remaining @entity1 , 104 were followed over 13.8      17.5  months with 3.5      2.3 visits during follow-up. Rhythm control was attempted in 10 @entity1 (9.6%). @entity1697 was initiated in 37 @entity1 (35.6 %). Fifty-nine (56.7%) @entity1 reached the primary composite endpoint. @entity64 / @entity385 (34.6%) and @entity712 (49%) were common. Subgroup analysis revealed no significant differences in any of the endpoints between @entity1 undergoing rhythm versus rate control and between @entity1 under @entity1697 compared with @entity1 without @entity1697 . INR at follow-up and TTR were 1.76      1.0 and 29.5%      37.8% in @entity1 receiving VKA. CONCLUSION: In this real-world cohort of very elderly @entity1 with @entity955 , a rhythm control strategy and @entity1697 treatment were chosen only in a minority of the cases. If @entity1697 was initiated, most received VKAs with a poor TTR during follow-up. A high incidence of @entity64 / @entity385 was observed in @entity1 with and without @entity1697 . Further data are needed to define optimal treatment of @entity955 in this particular @entity1 group.

Treatment of Nonagenarians With XXXX : Insights From the Berlin @entity955 (BAF) Registry.

@entity1 :: ('9606', 'Species') :: ['Patients', 'patients', 'patient', 'PARTICIPANTS'] @entity64 :: ('MESH:D020521', 'Disease') :: ['stroke', 'Stroke'] @entity712 :: ('MESH:D006333', 'Disease') :: ['heart failure'] @entity1697 :: ('MESH:D009062', 'Disease') :: ['OAC', 'Oral anticoagulation'] @entity548 :: ('MESH:D006470', 'Disease') :: ['major bleeding'] @entity1031 :: ('MESH:D013923', 'Disease') :: ['thromboembolic events'] @entity955 :: ('MESH:D001281', 'Disease') :: ['atrial fibrillation', 'Atrial Fibrillation', 'AF'] @entity204 :: ('MESH:D003643', 'Disease') :: ['death'] @entity1168 :: ('MESH:D001919', 'Disease') :: ['bradyarrhythmia'] @entity385 :: ('MESH:D002544', 'Disease') :: ['stroke/transient ischemic attack', 'TIA']
@entity955 :: (MESH:D001281,Disease) :: ['Atrial Fibrillation']
